| pubmed-article:8568623 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8568623 | lifeskim:mentions | umls-concept:C0042960 | lld:lifeskim |
| pubmed-article:8568623 | lifeskim:mentions | umls-concept:C0024554 | lld:lifeskim |
| pubmed-article:8568623 | lifeskim:mentions | umls-concept:C1549078 | lld:lifeskim |
| pubmed-article:8568623 | lifeskim:mentions | umls-concept:C1997894 | lld:lifeskim |
| pubmed-article:8568623 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:8568623 | lifeskim:mentions | umls-concept:C0001565 | lld:lifeskim |
| pubmed-article:8568623 | lifeskim:mentions | umls-concept:C0030095 | lld:lifeskim |
| pubmed-article:8568623 | lifeskim:mentions | umls-concept:C0005508 | lld:lifeskim |
| pubmed-article:8568623 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:8568623 | pubmed:dateCreated | 1996-3-7 | lld:pubmed |
| pubmed-article:8568623 | pubmed:abstractText | The aim of this investigation was to assess the bioavailability and pharmacokinetics of oxytocin in six male subjects after a sublingual dose of 400 int. units (684 micrograms) and after an intravenous dose of 1 int. unit (1.71 micrograms). After intravenous administration, the pharmacokinetic profile could be described with a two-compartment model. The distribution half-life was 0.049 +/- 0.106 h, the elimination half-life was 0.33 +/- 0.23 h, the total body clearance was 67.1 +/- 13.4 L h-1 and the volume of distribution was 33.2 +/- 28.1 L. After sublingual administration, a poor bioavailability with a 10-fold variation between 0.007 and 0.07% was observed. The pharmacokinetic profile could be described with a one-compartment model. The lag time was subject-dependent and ranged between 0.12 and 0.30 h (40% CV). The absorption half-life was 0.45 +/- 0.29 h, and the apparent elimination half-life 0.69 +/ - 0.26 h. This study showed a very poor and interindividual variability in bioavailability. The sublingual route of administration with its 'long' lag time and 'long' absorption half-life would not seem a reliable route for accurate high dosing for immediate prevention of post-partum haemorrhage. | lld:pubmed |
| pubmed-article:8568623 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8568623 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8568623 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8568623 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8568623 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8568623 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:8568623 | pubmed:issn | 0022-3573 | lld:pubmed |
| pubmed-article:8568623 | pubmed:author | pubmed-author:VreeT BTB | lld:pubmed |
| pubmed-article:8568623 | pubmed:author | pubmed-author:HeksterY AYA | lld:pubmed |
| pubmed-article:8568623 | pubmed:author | pubmed-author:PesmanG JGJ | lld:pubmed |
| pubmed-article:8568623 | pubmed:author | pubmed-author:Van... | lld:pubmed |
| pubmed-article:8568623 | pubmed:author | pubmed-author:De GrootA NAN | lld:pubmed |
| pubmed-article:8568623 | pubmed:author | pubmed-author:SweepF CFC | lld:pubmed |
| pubmed-article:8568623 | pubmed:author | pubmed-author:Van DongenP... | lld:pubmed |
| pubmed-article:8568623 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8568623 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:8568623 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8568623 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8568623 | pubmed:pagination | 571-5 | lld:pubmed |
| pubmed-article:8568623 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:meshHeading | pubmed-meshheading:8568623-... | lld:pubmed |
| pubmed-article:8568623 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8568623 | pubmed:articleTitle | Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. | lld:pubmed |
| pubmed-article:8568623 | pubmed:affiliation | Department of Gynaecology, Academic Hospital Nijmegan, Sint Radboud, The Netherlands. | lld:pubmed |
| pubmed-article:8568623 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8568623 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8568623 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:8568623 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
